Per capita spending on specialty drugs increased 55% between 2014 and 2018. Individuals aged 55 to 75 years using specialty drugs make the transition from employer-sponsored insurance (ESI) to Medicare Part D coverage. We compared out-of-pocket (OOP) spending across ESI, Medicare fee-for-service (FFS), and Medicare Advantage (MA) prescription drug plans to examine the impact of benefit design on OOP spending.
- Trump’s last-ditch drug pricing moves could help him in November. But they likely won’t save Americans money
- A Deal on Drug Prices Undone by White House Insistence on ‘Trump Cards’